Since SGLT2 inhibitors seem to be an attractive therapeutic opportunity for metabolic liver disease management, these findings come in support of a beneficial effect for empagliflozin in the regulation of hepatic metabolism in a context of obesity and diabetes. Here, SLC5A2 is linked to Obesity.